Neuroprotection in Parkinson's disease: Clinical trials

Fabrizio Stocchi, C. Warren Olanow, [No Value] Hunot, [No Value] Keiburtz, [No Value] Tatton, [No Value] Brooks, [No Value] Rascol, [No Value] Marek, [No Value] Schapiro

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Advances in our understanding of the cause and pathogenesis of Parkinson's disease (PD) have permitted the rational selection of putative neuroprotective agents for study in PD. However, the list of agents that might provide neuroprotective effects derived from laboratory studies is daunting, and we face the challenge of determining which agents to bring to the clinic and how to find the resources (patients and funds) to properly study so many promising therapeutic opportunities.1 Appropriate outcome variables that are not confounded by any symptomatic effect of the drug and are acceptable to clinicians and regulatory authorities also remain to be defined. The first clinical trials designed to test the capacity of putative neuroprotective agents to alter the natural history of PD have now been performed and illustrate some of these problems. The DATATOP (Deprenyl and Tocopherol Antioxidant Therapy of PD) study used the time to reach a disease milestone in untreated PD patients (ie, need for levodopa) as the primary end point. However, interpretation of results was confounded by the drug's symptomatic effect. The SINDEPAR (Sinemet-Deprenyl-Parlodel) study used the change in motor score between initial visit and final visit after washout of all study medications as the primary end point. However, here too there were concerns about confounding symptomatic effects, because antiparkinsonian medications have now been shown to have a long duration response that can persist for weeks and perhaps even months after withdrawal. More recent studies have used surrogate markers of the integrity of nigrostriatal function such as striatal uptake of fluorodopa on positron emission tomography (PET) or β-CIT-on single-photon emission computerized tomography (SPECT) as primary outcome measures. However, it has not yet been confirmed that striatal uptake of these isotopes does in fact correlate with the remaining number of dopamine neurons or terminals, and the possibility of a confounding pharmacological effect has not yet been completely excluded. To date, no drug has been established to have a neuroprotective effect in PD, and none has been approved for a neuroprotective indication. Furthermore, regulatory agencies have not yet agreed that any of the outcome measures currently used will be acceptable for approval of a new drug. Resolution of these issues is of critical importance to convince pharmaceutical companies to expend the hundreds of millions of dollars necessary to bring a new drug to market. Drugs that already have been approved in PD for their symptomatic effects, such as dopamine agonists or propargylamines (eg, selegiline), offer the best opportunity for establishing that a drug is neuroprotective in PD in the immediate future, but herein also lies the difficulty of establishing that any benefits observed are not solely because of the drug's symptomatic properties. Currently, this will most likely entail demonstrating that the drug provides benefit for PD patients for both imaging and clinical markers of disease progression.

Original languageEnglish
JournalAnnals of Neurology
Volume53
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Parkinson Disease
Clinical Trials
Neuroprotective Agents
Selegiline
Pharmaceutical Preparations
Corpus Striatum
Secondary Parkinson Disease
Biomarkers
Outcome Assessment (Health Care)
Antiparkinson Agents
Drug Approval
Tocopherols
Bromocriptine
Neuroprotection
Dopaminergic Neurons
Dopamine Agonists
Levodopa
Financial Management
Single-Photon Emission-Computed Tomography
Isotopes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Stocchi, F., Olanow, C. W., Hunot, N. V., Keiburtz, N. V., Tatton, N. V., Brooks, N. V., ... Schapiro, N. V. (2003). Neuroprotection in Parkinson's disease: Clinical trials. Annals of Neurology, 53(SUPPL. 3). https://doi.org/10.1002/ana.10488

Neuroprotection in Parkinson's disease : Clinical trials. / Stocchi, Fabrizio; Olanow, C. Warren; Hunot, [No Value]; Keiburtz, [No Value]; Tatton, [No Value]; Brooks, [No Value]; Rascol, [No Value]; Marek, [No Value]; Schapiro, [No Value].

In: Annals of Neurology, Vol. 53, No. SUPPL. 3, 01.04.2003.

Research output: Contribution to journalArticle

Stocchi, F, Olanow, CW, Hunot, NV, Keiburtz, NV, Tatton, NV, Brooks, NV, Rascol, NV, Marek, NV & Schapiro, NV 2003, 'Neuroprotection in Parkinson's disease: Clinical trials', Annals of Neurology, vol. 53, no. SUPPL. 3. https://doi.org/10.1002/ana.10488
Stocchi F, Olanow CW, Hunot NV, Keiburtz NV, Tatton NV, Brooks NV et al. Neuroprotection in Parkinson's disease: Clinical trials. Annals of Neurology. 2003 Apr 1;53(SUPPL. 3). https://doi.org/10.1002/ana.10488
Stocchi, Fabrizio ; Olanow, C. Warren ; Hunot, [No Value] ; Keiburtz, [No Value] ; Tatton, [No Value] ; Brooks, [No Value] ; Rascol, [No Value] ; Marek, [No Value] ; Schapiro, [No Value]. / Neuroprotection in Parkinson's disease : Clinical trials. In: Annals of Neurology. 2003 ; Vol. 53, No. SUPPL. 3.
@article{abe76a74b65d4da28e5cc3f1cbf4bcca,
title = "Neuroprotection in Parkinson's disease: Clinical trials",
abstract = "Advances in our understanding of the cause and pathogenesis of Parkinson's disease (PD) have permitted the rational selection of putative neuroprotective agents for study in PD. However, the list of agents that might provide neuroprotective effects derived from laboratory studies is daunting, and we face the challenge of determining which agents to bring to the clinic and how to find the resources (patients and funds) to properly study so many promising therapeutic opportunities.1 Appropriate outcome variables that are not confounded by any symptomatic effect of the drug and are acceptable to clinicians and regulatory authorities also remain to be defined. The first clinical trials designed to test the capacity of putative neuroprotective agents to alter the natural history of PD have now been performed and illustrate some of these problems. The DATATOP (Deprenyl and Tocopherol Antioxidant Therapy of PD) study used the time to reach a disease milestone in untreated PD patients (ie, need for levodopa) as the primary end point. However, interpretation of results was confounded by the drug's symptomatic effect. The SINDEPAR (Sinemet-Deprenyl-Parlodel) study used the change in motor score between initial visit and final visit after washout of all study medications as the primary end point. However, here too there were concerns about confounding symptomatic effects, because antiparkinsonian medications have now been shown to have a long duration response that can persist for weeks and perhaps even months after withdrawal. More recent studies have used surrogate markers of the integrity of nigrostriatal function such as striatal uptake of fluorodopa on positron emission tomography (PET) or β-CIT-on single-photon emission computerized tomography (SPECT) as primary outcome measures. However, it has not yet been confirmed that striatal uptake of these isotopes does in fact correlate with the remaining number of dopamine neurons or terminals, and the possibility of a confounding pharmacological effect has not yet been completely excluded. To date, no drug has been established to have a neuroprotective effect in PD, and none has been approved for a neuroprotective indication. Furthermore, regulatory agencies have not yet agreed that any of the outcome measures currently used will be acceptable for approval of a new drug. Resolution of these issues is of critical importance to convince pharmaceutical companies to expend the hundreds of millions of dollars necessary to bring a new drug to market. Drugs that already have been approved in PD for their symptomatic effects, such as dopamine agonists or propargylamines (eg, selegiline), offer the best opportunity for establishing that a drug is neuroprotective in PD in the immediate future, but herein also lies the difficulty of establishing that any benefits observed are not solely because of the drug's symptomatic properties. Currently, this will most likely entail demonstrating that the drug provides benefit for PD patients for both imaging and clinical markers of disease progression.",
author = "Fabrizio Stocchi and Olanow, {C. Warren} and Hunot, {[No Value]} and Keiburtz, {[No Value]} and Tatton, {[No Value]} and Brooks, {[No Value]} and Rascol, {[No Value]} and Marek, {[No Value]} and Schapiro, {[No Value]}",
year = "2003",
month = "4",
day = "1",
doi = "10.1002/ana.10488",
language = "English",
volume = "53",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Neuroprotection in Parkinson's disease

T2 - Clinical trials

AU - Stocchi, Fabrizio

AU - Olanow, C. Warren

AU - Hunot, [No Value]

AU - Keiburtz, [No Value]

AU - Tatton, [No Value]

AU - Brooks, [No Value]

AU - Rascol, [No Value]

AU - Marek, [No Value]

AU - Schapiro, [No Value]

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Advances in our understanding of the cause and pathogenesis of Parkinson's disease (PD) have permitted the rational selection of putative neuroprotective agents for study in PD. However, the list of agents that might provide neuroprotective effects derived from laboratory studies is daunting, and we face the challenge of determining which agents to bring to the clinic and how to find the resources (patients and funds) to properly study so many promising therapeutic opportunities.1 Appropriate outcome variables that are not confounded by any symptomatic effect of the drug and are acceptable to clinicians and regulatory authorities also remain to be defined. The first clinical trials designed to test the capacity of putative neuroprotective agents to alter the natural history of PD have now been performed and illustrate some of these problems. The DATATOP (Deprenyl and Tocopherol Antioxidant Therapy of PD) study used the time to reach a disease milestone in untreated PD patients (ie, need for levodopa) as the primary end point. However, interpretation of results was confounded by the drug's symptomatic effect. The SINDEPAR (Sinemet-Deprenyl-Parlodel) study used the change in motor score between initial visit and final visit after washout of all study medications as the primary end point. However, here too there were concerns about confounding symptomatic effects, because antiparkinsonian medications have now been shown to have a long duration response that can persist for weeks and perhaps even months after withdrawal. More recent studies have used surrogate markers of the integrity of nigrostriatal function such as striatal uptake of fluorodopa on positron emission tomography (PET) or β-CIT-on single-photon emission computerized tomography (SPECT) as primary outcome measures. However, it has not yet been confirmed that striatal uptake of these isotopes does in fact correlate with the remaining number of dopamine neurons or terminals, and the possibility of a confounding pharmacological effect has not yet been completely excluded. To date, no drug has been established to have a neuroprotective effect in PD, and none has been approved for a neuroprotective indication. Furthermore, regulatory agencies have not yet agreed that any of the outcome measures currently used will be acceptable for approval of a new drug. Resolution of these issues is of critical importance to convince pharmaceutical companies to expend the hundreds of millions of dollars necessary to bring a new drug to market. Drugs that already have been approved in PD for their symptomatic effects, such as dopamine agonists or propargylamines (eg, selegiline), offer the best opportunity for establishing that a drug is neuroprotective in PD in the immediate future, but herein also lies the difficulty of establishing that any benefits observed are not solely because of the drug's symptomatic properties. Currently, this will most likely entail demonstrating that the drug provides benefit for PD patients for both imaging and clinical markers of disease progression.

AB - Advances in our understanding of the cause and pathogenesis of Parkinson's disease (PD) have permitted the rational selection of putative neuroprotective agents for study in PD. However, the list of agents that might provide neuroprotective effects derived from laboratory studies is daunting, and we face the challenge of determining which agents to bring to the clinic and how to find the resources (patients and funds) to properly study so many promising therapeutic opportunities.1 Appropriate outcome variables that are not confounded by any symptomatic effect of the drug and are acceptable to clinicians and regulatory authorities also remain to be defined. The first clinical trials designed to test the capacity of putative neuroprotective agents to alter the natural history of PD have now been performed and illustrate some of these problems. The DATATOP (Deprenyl and Tocopherol Antioxidant Therapy of PD) study used the time to reach a disease milestone in untreated PD patients (ie, need for levodopa) as the primary end point. However, interpretation of results was confounded by the drug's symptomatic effect. The SINDEPAR (Sinemet-Deprenyl-Parlodel) study used the change in motor score between initial visit and final visit after washout of all study medications as the primary end point. However, here too there were concerns about confounding symptomatic effects, because antiparkinsonian medications have now been shown to have a long duration response that can persist for weeks and perhaps even months after withdrawal. More recent studies have used surrogate markers of the integrity of nigrostriatal function such as striatal uptake of fluorodopa on positron emission tomography (PET) or β-CIT-on single-photon emission computerized tomography (SPECT) as primary outcome measures. However, it has not yet been confirmed that striatal uptake of these isotopes does in fact correlate with the remaining number of dopamine neurons or terminals, and the possibility of a confounding pharmacological effect has not yet been completely excluded. To date, no drug has been established to have a neuroprotective effect in PD, and none has been approved for a neuroprotective indication. Furthermore, regulatory agencies have not yet agreed that any of the outcome measures currently used will be acceptable for approval of a new drug. Resolution of these issues is of critical importance to convince pharmaceutical companies to expend the hundreds of millions of dollars necessary to bring a new drug to market. Drugs that already have been approved in PD for their symptomatic effects, such as dopamine agonists or propargylamines (eg, selegiline), offer the best opportunity for establishing that a drug is neuroprotective in PD in the immediate future, but herein also lies the difficulty of establishing that any benefits observed are not solely because of the drug's symptomatic properties. Currently, this will most likely entail demonstrating that the drug provides benefit for PD patients for both imaging and clinical markers of disease progression.

UR - http://www.scopus.com/inward/record.url?scp=0037378740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037378740&partnerID=8YFLogxK

U2 - 10.1002/ana.10488

DO - 10.1002/ana.10488

M3 - Article

C2 - 12666101

AN - SCOPUS:0037378740

VL - 53

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - SUPPL. 3

ER -